uDesis™

synthetic bone substitute



Can be used for filling or accreting to ulrich medical spinal systems


ulrich medical

dedicated to you.

Synthetic bone substitute

uDesis as alternative to autograft bone

uDesis is a synthetic, highly crystalline beta-tricalcium phosphate bone replacement material. uDesis is used by orthopedic surgeons treating defects of the skeleton such as fractures and in specialist surgical techniques such as spine surgery. uDesis is successfully used in place of autologous, allogenic or xenogenous bone material. uDesis is completely remodeled into autograft bone.



Advantages

Individual malleability

uDesis can be molded as required and is therefore ideal for modeling on spinal systems. Clean and easy handling without adhesion to gloves is guaranteed.

Easy to apply

uDesis Gel is ready to use and can be applied immediately. This saves time in the OR.

Micropores for remodeling processes


uDesis achieves a larger surface due to microporosity (0.001 - 0.100 mm). This supports the remodeling processes of the material by the body's own cells.

Osteoconductive

The three-dimensional, highly porous structure of uDesis supports the cell proliferation and serves as a guide rail for bone remodelling.

Reliable application

uDesis remains in position, even in contact with bodily fluids.



Accretion to the bone


The gel allows the filling of and accretion to implants with maximum possible contact between bone and bone subsitute.



Physiological resorption process of uDesis™


Interconnected macropores

The sizes of uDesis macropores range from 0.1 to 1.0 mm. Vascularization and the migration of osteoclasts and osteoblasts can thus take place effectively (Gazdag, 1995).



Fully resorbable

uDesis is gradually resorbed and converted into the body's own bone substance through physiological cellular processes. Approximately 12 weeks after implantation, uDesis has mostly been remodeled into the body's own bone substance.





Indications


uDesis Gel is intended to be used to fill bony voids occurring in the skeletal system which are not intrinsic to the stability of the bone structure.

Areas of application

uDesis is used for filling or accreting to spinal systems during spinal fusions.

uDesis is used to fill bone defects or gaps resulting from:

- surgical procedures
- traumatic bone injuries
- removal of a cyst
- removal of a tumor
- osteotomies or fracture reductions



Components

Gel	Volume	Product no.
uDesis Gel, synthetic bone substitute	1 cc	CS 6604-010
uDesis Gel, synthetic bone substitute	2,5 cc	CS 6604-025
uDesis Gel, synthetic bone substitute	5 cc	CS 6604-05
uDesis Gel, synthetic bone substitute	10 cc	CS 6604-10

Clinical References

Stephan Becker, MD, Otto Maissen, MD Vet, Ponomarev Igor, PhD, Stoll Thierry, MSc Eng, Berton Rahn, MD, MD Dent, and Wilke Ingo, PhD (2006): Osteopromotion by a ß-Tricalcium Phophate/Bone Marrow Hybrid Implant for Use in Spine Surgery. Spine 2006 Volume 31, Number 1. pp 11-17

Joel Delécrin, MD, PhD, Shinobu Takahashi, MD, PhD, François Gouin, MD, and Norbert Passuti, MD, PhD (2000): A Synthetic Porous Ceramic as a Bone Graft Substitute in the Surgical Management of Scoliosis: A Prospective, Randomized Study. Spine 2000 Volume 25, Number 5. pp 563-569

Scott D. Boden (2002): Overview of the Biology of Lumbar Spine Fusion and Principles for Selecting a Bone Graft Substitute. Spine 2002, Vol 27, Number 165. pp. S26-S31 2002

Gazdag AR, Lane JM, Glaser D, Forster RA. Alternatives to Autogenous Bone Graft: Efficacy and Indications. J Am Acad Orthop Surg. 1995 Jan;3(1):S. 1-8.

B. N Summers, S. M Eisenstein (1989): Donor Site Pain from the Ilium: A Complication of Lumbar Spine Fusion. J Bone Joint Surg [Br]. 71-B: 677-680

J. C. Le Huec, E. Lesprit, C. Delavigne, D. Clement, D. Chauveaux, A. Le Rebeller (1997): Tri-Calcium phosphate ceramics and allografts as bone substitutes for spinal fusion in idiopathic scoliosis: Comparative clinical results at four years. Acta Orthopoedica Belgica, Vol. 63 – 3 – 1997

Edward M. Younger, Michael W. Chapman (1989): Morbidity at Bone Graft Donor Sites. Journal of Orthopaedic Trauma, Vol. 3, No. 3. pp. 192-195

tcma Orthobiologics

3 Hillgrove Business Park, Nazeing Road, Nazeing
Essex, EN9 2HB, United Kingdom
Telefon/Phone: +44 (0)1992 892 085
info@tcma.co.uk

With reservations of technical changes, misprints and errors The country-specific availability of articles must be taken into consideration.

Distributed by:

ulrich GmbH & Co. KG
Buchbrunnenweg 12
89081 Ulm, Germany
T +49 731 9654-0
spine@ulrichmedical.com
www.ulrichmedical.com

ulrich medical France SAS
10, Allée Aristide Maillol
31770 Colomiers, France
T +33 5 61 86 09 92
info@ulrichmedical.fr
www.ulrichmedical.fr

WS 6600-EN R03/2026-09